A focus on dominant negative variants in a series of 170 heterozygous FXI-deficient patients

Haemophilia. 2023 Jul;29(4):1113-1120. doi: 10.1111/hae.14802. Epub 2023 May 30.

Abstract

Introduction: Dominant-negative effects have been described for 10 F11 variants in the literature.

Aim: The current study aimed at identifying putative dominant-negative F11 variants.

Material and methods: This research consisted in a retrospective analysis of routine laboratory data.

Results: In a series of 170 patients with moderate/mild factor XI (FXI) deficiencies, we identified heterozygous carriers of previously reported dominant-negative variants (p.Ser243Phe, p.Cys416Tyr, and p.Gly418Val) with FXI activities inconsistent with a dominant-negative effect. Our findings also do not support a dominant-negative effect of p.Gly418Ala. We also identified a set of patients carrying heterozygous variants, among which five out of 11 are novel, with FXI activities suggesting a dominant-negative effect (p.His53Tyr, p.Cys110Gly, p.Cys140Tyr, p.Glu245Lys, p.Trp246Cys, p.Glu315Lys, p.Ile421Thr, p.Trp425Cys, p.Glu565Lys, p.Thr593Met, and p.Trp617Ter). However, for all but two of these variants, individuals with close to half normal FXI coagulant activity (FXI:C) were identified, indicating an inconstant dominant effect.

Conclusion: Our data show that for some F11 variants recognized has having dominant-negative effects, such effects actually do not occur in many individuals. The present data suggest that for these patients, the intracellular quality control mechanisms eliminate the variant monomeric polypeptide before homodimer assembly, thereby allowing only the wild-type homodimer to assemble and resulting in half normal activities. In contrast, in patients with markedly decreased activities, some mutant polypeptides might escape this first quality control. In turn, assembly of heterodimeric molecules as well as mutant homodimers would result in activities closer to 1:4 of FXI:C normal range.

Keywords: F11 gene; F11 variant; FXI deficiency; HPO 0001928 Abnormality of coagulation; HPO 0003256 Abnormality of the coagulation cascade; dominant negative variant.

MeSH terms

  • Factor XI Deficiency* / genetics
  • Factor XI* / genetics
  • Heterozygote
  • Humans
  • Pedigree
  • Retrospective Studies

Substances

  • Factor XI